Literature DB >> 21771721

Inflammation-induced loss of Pdcd4 is mediated by phosphorylation-dependent degradation.

Tobias Schmid1, Magdalena M Bajer, Johanna S Blees, Lisa K Eifler, Larissa Milke, Daniela Rübsamen, Kathrin Schulz, Andreas Weigert, Alyson R Baker, Nancy H Colburn, Bernhard Brüne.   

Abstract

The tumor suppressor programmed cell death 4 (Pdcd4) is lost in various tumor tissues. Loss of Pdcd4 has been associated with increased tumorigenic potential and tumor progression. While various mechanisms of Pdcd4 regulation have been described, the effect of an inflammatory tumor microenvironment on Pdcd4 protein expression has not been characterized so far. In the present study, we aimed to elucidate the molecular mechanisms of Pdcd4 protein regulation in tumor cells under inflammatory conditions. 12-O-tetradecanoylphorbol 13-acetate-induced differentiation of human U937 monocytes increased the expression and secretion of inflammatory cytokines such as tumor necrosis factor α, interleukin (IL)-6 and IL-8. Exposure to conditioned medium (CM) of these activated macrophages markedly decreased Pdcd4 protein expression in various tumor cells. Similarly, indirect coculture with such activated U937 monocyte-derived macrophages resulted in the loss of Pdcd4 protein in tumor cells. Decreased Pdcd4 protein levels were attributable to enhanced proteasomal degradation, diminishing Pdcd4 protein half-life. Proteasomal degradation required activation of phosphatidylinositol-3-kinase (PI3K)-mammalian target of rapamycin (mTOR) signaling. Since macrophage-CM sufficed to induce Pdcd4 degradation, Pdcd4 downregulation was determined to be an indirect unidirectional effect of the macrophages on the tumor cells. Pdcd4 protein expression was also attenuated in vivo in mouse colon tissue in response to dextran sodium sulfate-induced colitis. In summary, we characterized PI3K-mTOR-dependent proteasome-mediated Pdcd4 degradation in tumor cells in the inflammatory tumor microenvironment. Consequently, stabilization of Pdcd4 protein could provide a promising novel avenue for therapeutics targeting inflammation-associated tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771721      PMCID: PMC3179419          DOI: 10.1093/carcin/bgr131

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  45 in total

1.  The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure.

Authors:  Y V Svitkin; A Pause; A Haghighat; S Pyronnet; G Witherell; G J Belsham; N Sonenberg
Journal:  RNA       Date:  2001-03       Impact factor: 4.942

2.  Cancer: an inflammatory link.

Authors:  Fran Balkwill; Lisa M Coussens
Journal:  Nature       Date:  2004-09-23       Impact factor: 49.962

3.  Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4.

Authors:  Anja Hilliard; Brendan Hilliard; Shi-Jun Zheng; Honghong Sun; Takashi Miwa; Wenchao Song; Rüdiger Göke; Youhai H Chen
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

4.  The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation.

Authors:  Hsin-Sheng Yang; Aaron P Jansen; Anton A Komar; Xiaojing Zheng; William C Merrick; Sylvain Costes; Stephen J Lockett; Nahum Sonenberg; Nancy H Colburn
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

5.  S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth.

Authors:  N Valerio Dorrello; Angelo Peschiaroli; Daniele Guardavaccaro; Nancy H Colburn; Nicholas E Sherman; Michele Pagano
Journal:  Science       Date:  2006-10-20       Impact factor: 47.728

6.  Potential markers of tongue tumor progression selected by cDNA microarray.

Authors:  F Carinci; L Lo Muzio; A Piattelli; C Rubini; F Chiesa; F Ionna; A Palmieri; E Maiorano; A Pastore; G Laino; M Dolci; F Pezzetti
Journal:  Int J Immunopathol Pharmacol       Date:  2005 Jul-Sep       Impact factor: 3.219

7.  Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion.

Authors:  Hsin-Sheng Yang; Connie P Matthews; Timothy Clair; Qing Wang; Alyson R Baker; Chou-Chi H Li; Tse-Hua Tan; Nancy H Colburn
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

8.  Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.

Authors:  Aaron P Jansen; Corinne E Camalier; Nancy H Colburn
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

9.  Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity.

Authors:  Aaron P Jansen; Corinne E Camalier; Cristi Stark; Nancy H Colburn
Journal:  Mol Cancer Ther       Date:  2004-02       Impact factor: 6.261

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more
  20 in total

1.  Protein kinase GSK3β regulates tumor suppressor Pdcd4 expression in lung cancer cells.

Authors:  P N Vikhreva; E V Korobko; I V Korobko
Journal:  Dokl Biochem Biophys       Date:  2012-03-15       Impact factor: 0.788

2.  Role of microRNA-21 and programmed cell death 4 in the pathogenesis of human uterine leiomyomas.

Authors:  J Browning Fitzgerald; Vargheese Chennathukuzhi; Faezeh Koohestani; Romana A Nowak; Lane K Christenson
Journal:  Fertil Steril       Date:  2012-06-22       Impact factor: 7.329

3.  LPS induces the degradation of programmed cell death protein 4 (PDCD4) to release Twist2, activating c-Maf transcription to promote interleukin-10 production.

Authors:  Mirjam W M van den Bosch; Eva Palsson-Mcdermott; Derek S Johnson; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2014-06-30       Impact factor: 5.157

4.  Cryptocaryol Structure-Activity Relationship Study of Cancer Cell Cytotoxicity and Ability to Stabilize PDCD4.

Authors:  Michael F Cuccarese; Yanping Wang; Penny J Beuning; George A O'Doherty
Journal:  ACS Med Chem Lett       Date:  2014-02-17       Impact factor: 4.345

5.  Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression.

Authors:  Ashish Saxena; Mohammad Shoeb; Kota V Ramana; Satish K Srivastava
Journal:  Eur J Cancer       Date:  2013-07-01       Impact factor: 9.162

6.  IRES-dependent translation of egr2 is induced under inflammatory conditions.

Authors:  Daniela Rübsamen; Johanna S Blees; Kathrin Schulz; Claudia Döring; Martin-Leo Hansmann; Heinrich Heide; Andreas Weigert; Tobias Schmid; Bernhard Brüne
Journal:  RNA       Date:  2012-08-22       Impact factor: 4.942

7.  Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor.

Authors:  Magdalena M Bajer; Michael M Kunze; Johanna S Blees; Heidi R Bokesch; Hanyong Chen; Thilo F Brauss; Zigang Dong; Kirk R Gustafson; Ricardo M Biondi; Curtis J Henrich; James B McMahon; Nancy H Colburn; Tobias Schmid; Bernhard Brüne
Journal:  Biochem Pharmacol       Date:  2014-02-07       Impact factor: 5.858

8.  BRD7 plays an anti-inflammatory role during early acute inflammation by inhibiting activation of the NF-кB signaling pathway.

Authors:  Ran Zhao; Yukun Liu; Heran Wang; Jing Yang; Weihong Niu; Songqing Fan; Wei Xiong; Jian Ma; Xiaoling Li; Joshua B Phillips; Ming Tan; Yuanzheng Qiu; Guiyuan Li; Ming Zhou
Journal:  Cell Mol Immunol       Date:  2016-07-04       Impact factor: 11.530

9.  Erioflorin stabilizes the tumor suppressor Pdcd4 by inhibiting its interaction with the E3-ligase β-TrCP1.

Authors:  Johanna S Blees; Heidi R Bokesch; Daniela Rübsamen; Kathrin Schulz; Larissa Milke; Magdalena M Bajer; Kirk R Gustafson; Curtis J Henrich; James B McMahon; Nancy H Colburn; Tobias Schmid; Bernhard Brüne
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

10.  Adiponectin induces A20 expression in adipose tissue to confer metabolic benefit.

Authors:  Laura E Hand; Paola Usan; Garth J S Cooper; Lance Y Xu; Basil Ammori; Peter S Cunningham; Reza Aghamohammadzadeh; Handrean Soran; Adam Greenstein; Andrew S I Loudon; David A Bechtold; David W Ray
Journal:  Diabetes       Date:  2014-09-04       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.